Treatment of navitoclax-sensitive or resistant BCL2Low NHL cell lines (SU-DHL-8, SU-DHL-10 and OCI-Ly-7) with navitoclax or A-1155463 resulted in dissociation of BIM from BCL-XL and enhanced MCL-1:BIM interactions (Figure 3b). This evidence concerns the gene BCL2L1 and non-Hodgkin lymphoma.